Boston Scientific (NYSE:BSX) Shares Unloaded Sen. John Boozman

Senator John Boozman (R-Arkansas) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 13th, the Senator disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on December 17th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 12/31/2025.
• Sold $1,001 – $15,000 in shares of Super Micro Computer (NASDAQ:SMCI) on 12/31/2025.
• Sold $1,001 – $15,000 in shares of SPDR S&P Regional Banking ETF (NYSEARCA:KRE) on 12/26/2025.
• Purchased $1,001 – $15,000 in shares of iShares Core S&P Small-Cap ETF (NYSEARCA:IJR) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of iShares Silver Trust (NYSEARCA:SLV) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of abrdn Physical Platinum Shares ETF (NYSEARCA:PPLT) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 12/24/2025.
• Purchased $15,001 – $50,000 in shares of Tradr 2X Long SPY Monthly ETF (NASDAQ:SPYM) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Motorola Solutions (NYSE:MSI) on 12/17/2025.
• Purchased $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 12/17/2025.

Boston Scientific Stock Down 4.0%

NYSE BSX traded down $3.75 during trading hours on Thursday, reaching $90.00. 27,776,049 shares of the company traded hands, compared to its average volume of 10,279,929. The company has a 50 day moving average of $97.32 and a two-hundred day moving average of $100.53. The stock has a market capitalization of $133.41 billion, a PE ratio of 48.13, a PEG ratio of 1.67 and a beta of 0.67. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,095 shares of company stock valued at $9,305,450 over the last three months. 0.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Robert W. Baird raised their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a report on Friday, October 17th. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, Leerink Partners raised their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Buy” and a consensus price target of $125.21.

Institutional Trading of Boston Scientific

Several large investors have recently modified their holdings of BSX. Steph & Co. acquired a new stake in shares of Boston Scientific in the third quarter worth $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth about $26,000. Finally, Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Strategic upside — the Penumbra deal adds mechanical thrombectomy and neurovascular capabilities, strengthening BSX’s cardiovascular and neuro offerings and supporting long‑term market share gains. Boston Scientific: Reclaiming Neurovascular Dominance Through Thrombectomy Precision
• Positive Sentiment: Analyst and strategic support — several analyst notes and M&A commentary frame the acquisition as a logical step to dominate thrombectomy and fast‑growing vascular segments, which could underpin longer‑term revenue growth. Boston Scientific Acquiring Penumbra Was The Logical Next Step
• Positive Sentiment: Other product/portfolio catalysts — recent FDA CE approvals and the Valencia Technologies deal (adds the eCoin ITNS device for urology) provide nearer‑term growth drivers independent of the Penumbra transaction. Boston Scientific to buy incontinence device maker Valencia
• Neutral Sentiment: Deal mechanics and official release — Boston Scientific announced a definitive agreement valuing Penumbra at roughly $14.5B (cash + stock) and held a conference call to discuss details; specifics on financing, expected synergies, and regulatory timeline will drive market interpretation. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Neutral Sentiment: M&A materials available — investor slides and the M&A call slideshow provide management’s rationale and integration plans (useful for modeling synergies and timing). Boston Scientific Corporation (BSX) Penumbra, Inc. – M&A Call – Slideshow
• Negative Sentiment: Near‑term negative market reaction — investors sold BSX on the announcement (while Penumbra jumped), reflecting concerns about deal size, near‑term dilution from the stock component, and integration execution risk. Boston Scientific to buy Penumbra in deal valued at $14.5 billion
• Negative Sentiment: Options and sentiment pressure — abnormally large put option volume was reported (big increase vs. typical daily put activity), indicating elevated short‑term bearish positioning and hedging that can amplify downward moves.
• Negative Sentiment: Potential legal/registry overhang — third‑party notices about investigations related to Penumbra were circulated (may raise diligence/regulatory/legal questions that investors will watch). BRODSKY & SMITH SHAREHOLDER UPDATE

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.